AZD7762

Catalog No.S1532

Molecular Weight(MW): 362.42

AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM in a cell-free assay. It is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. Phase 1.

Cited by 35 Publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Discov, 2012, 2(6):524-39

PubMed: 22628408 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(6):542-6

PubMed: 21623355 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(6):1032-1045

PubMed: 30771522 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):762-770

PubMed: 30872379 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:195

PubMed: 31372095 ( click the link to review the publication )

Cell Cycle, 2019, 18(8):834-847

PubMed: 30943845 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5029-5049

PubMed: 29596642 ( click the link to review the publication )

Cancer Lett, 2018, 431:142-149

PubMed: 29859297 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(7):612-618

PubMed: 29897742 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1392

PubMed: 29123096 ( click the link to review the publication )

Haematologica, 2017, 102(5):826-834

PubMed: 28154085 ( click the link to review the publication )

Cancer Lett, 2017, 392:71-82

PubMed: 28126323 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):1

PubMed: 28049532 ( click the link to review the publication )

Eur J Pharm Sci, 2017, 109:223-232

PubMed: 28822757 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3319-31

PubMed: 26988986 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):437-47

PubMed: 26979711 ( click the link to review the publication )

J Biol Chem, 2016, 291(17):9330-42

PubMed: 26940878 ( click the link to review the publication )

Anticancer Res, 2016, 36(6):2649-57

PubMed: 27272773 ( click the link to review the publication )

J Pathol, 2015, 10.1002/path.4528

PubMed: 25757065 ( click the link to review the publication )

Biochem Pharmacol, 2015, 93(2):210-20

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(25):21074-84

PubMed: 26025928 ( click the link to review the publication )

Cell Rep, 2014, 10.1016/j.celrep.2014.10.024

PubMed: ( click the link to review the publication )
Sci Signal, 2014, 7(326):ra47

PubMed: 24847116 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1253

PubMed: 24853431 ( click the link to review the publication )

Int J Oncol, 2014, 45(3):1159-66

PubMed: 24969815 ( click the link to review the publication )

Int J Gynecol Cancer, 2014, 24(5):838-43

PubMed: 24804869 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10546-57

PubMed: 25301733 ( click the link to review the publication )

Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

J Cell Mol Med, 2013, 18(1):143-55

PubMed: 24238094 ( click the link to review the publication )

PLoS One, 2013, 8(2):e55493

PubMed: 23405159 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(6):379-88

PubMed: 22313687 ( click the link to review the publication )

Cancer Biol Ther, 2011, 12(3):215-28

PubMed: 21642769 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Chk Inhibitors

Biological Activity

Description

AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM in a cell-free assay. It is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. Phase 1.

Targets

Chk1 ^[1] (Cell-free assay)	Chk2 ^[1] (Cell-free assay)
5 nM	<10 nM

In vitro

AZD7762, a more selective Chk1 inhibitor, inhibits Chk1 phosphorylation of a cdc25C peptide by reversibly binding to the ATP-binding site of Chk1, with IC50 of 5 nM and K_i of 3.6 nM. AZD7762 induces cell arrest with EC50 of 0.620 μM, and significantly abrogates the camptothecin induced G2 arrest with an EC50 of 10 nM, by blocking the chk1 dependent degradation of Cdc25A and activation of Cyclin A. AZD7762 (300 nM) enhances the antitumor efficacy of gemcitabine against SW620 and topotecan against MDA-MB-231 by reducing the GI50 values from 24.1 nM and 2.25 μM to 1.08 nM and 0.15 μM, respectively. ^[1] AZD7762 shows cytotoxicity against a variety of neuroblastoma cell lines bearing p53 wild type, p53 mutation, Mdm2 amplification or p14 deletion with IC50 values ranging from 82.6-505.9 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KASUMI-1	MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwMECwNlM1KM7:TR?=	MonkV2FPT0WU
NKM-1	M1jzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3KSplKSzVyPUCuNFAxPDF3IN88US=>	NFOxOXdUSU6JRWK=
MV-4-11	NGH6Zm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHMTWM2OD1yLkCwNFQzPSEQvF2=	M{LrfXNCVkeHUh?=
NCI-H1703	M1PPWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33PXGlEPTB;MD6wNFY1OyEQvF2=	MUfTRW5ITVJ?
A204	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vuTWlEPTB;MD6wNFg2PiEQvF2=	NHzifpBUSU6JRWK=
CGTH-W-1	NIL4flZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;tUGlEPTB;MD6wNVQzKM7:TR?=	M1XOU3NCVkeHUh?=
MLMA	Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwMEK4OFkh\|ryP	NH7ySo9USU6JRWK=
GOTO	NFi4bHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHiTWM2OD1yLkCzNVIh\|ryP	MnHOV2FPT0WU
KE-37	Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzhRolKSzVyPUCuNFMyPDJizszN	NVvqd5hEW0GQR1XS
ES4	NGHOUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlm5TWM2OD1yLkCzNlUyKM7:TR?=	NW\xbW9SW0GQR1XS
ATN-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMEO0NVch\|ryP	NIfReoNUSU6JRWK=
MHH-PREB-1	M{\3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDafnJKSzVyPUCuNFM1PDJizszN	NW\FR\|d5W0GQR1XS
SW756	M1q5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPxTWM2OD1yLkCzOVc6KM7:TR?=	M4fuWnNCVkeHUh?=
CTV-1	M1v4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDO[VZKSzVyPUCuNFM5QTZizszN	NEfuRo5USU6JRWK=
HCC1806	NGnTVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLhTWM2OD1yLkC0NFIzKM7:TR?=	MYfTRW5ITVJ?
NEC8	MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfUS\|NKSzVyPUCuNFQzODNizszN	Mn3FV2FPT0WU
P12-ICHIKAWA	NXj1O2JuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HZcWlEPTB;MD6wOFMyPiEQvF2=	NHnQbZFUSU6JRWK=
DEL	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\vdHZtUUN3ME2wMlA1PTl{IN88US=>	NEm2V5BUSU6JRWK=
KM12	NHzlXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1uxfWlEPTB;MD6wOVE2QCEQvF2=	MXzTRW5ITVJ?
LB1047-RCC	M3\qUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY[zXlBJUUN3ME2wMlA3ODJ3IN88US=>	NXTNPZlKW0GQR1XS
LB2241-RCC	MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfPOWtRUUN3ME2wMlA3OTB{IN88US=>	MkjlV2FPT0WU
NOMO-1	M1Lrdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHOwWYpKSzVyPUCuNFYyOTVizszN	MUPTRW5ITVJ?
NB14	NGDr[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwME[xN\|Yh\|ryP	M1PGd3NCVkeHUh?=
ONS-76	NULZRZc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PTW2lEPTB;MD6wOlE6PiEQvF2=	Mme5V2FPT0WU
HD-MY-Z	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwME[yOVUh\|ryP	M3XMTnNCVkeHUh?=
G-402	MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwME[0OkDPxE1?	NV64W2xJW0GQR1XS
ES1	MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHNb5pRUUN3ME2wMlA4OTR4IN88US=>	MnLOV2FPT0WU
L-363	Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTBTWM2OD1yLkC3N\|kh\|ryP	NF;jT5VUSU6JRWK=
A4-Fuk	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLaTWM2OD1yLkC3OFg3KM7:TR?=	MXLTRW5ITVJ?
OC-314	NG[xWpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXuTWM2OD1yLkC3PFA4KM7:TR?=	MVzTRW5ITVJ?
SK-LU-1	MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHZTWM2OD1yLkC4OFIyKM7:TR?=	NGG2cHFUSU6JRWK=
MDA-MB-157	NGjpPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;ZTWM2OD1yLkC4OlU6KM7:TR?=	NInlUXpUSU6JRWK=
HuP-T3	NGLUT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTBwMEi3NUDPxE1?	MoDKV2FPT0WU
A3-KAW	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMEi4NFYh\|ryP	NGfw[VlUSU6JRWK=
MOLT-16	M4C2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7LWFRKSzVyPUCuNFg5ODdizszN	MkDOV2FPT0WU
COLO-679	NFTjbZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlT4TWM2OD1yLkC5NFkyKM7:TR?=	MlnaV2FPT0WU
EM-2	NV\ET\|RpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwMEm5NFMh\|ryP	NULMPGs5W0GQR1XS
ES8	M4raTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1L0c2lEPTB;MD6wPVkyQCEQvF2=	NFHVcIVUSU6JRWK=
SK-MEL-2	M1vnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUC1cZRpUUN3ME2wMlExODN\|IN88US=>	NG\mVlFUSU6JRWK=
ES3	NH;XZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwMUCyJO69VQ>?	MnP3V2FPT0WU
HSC-4	M4Hufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMUC1OVQh\|ryP	MkL4V2FPT0WU
697	NVP2OlNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwMUGwOlMh\|ryP	NHjPT3NUSU6JRWK=
TGBC11TKB	Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDU[o1{UUN3ME2wMlEyODl\|IN88US=>	NVnifWlFW0GQR1XS
SK-PN-DW	NVTnb5c4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvDSW5TUUN3ME2wMlEyQDZizszN	MXfTRW5ITVJ?
H9	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPJZmk2UUN3ME2wMlEzOTZ3IN88US=>	MorOV2FPT0WU
NCI-H2122	MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnIVXRqUUN3ME2wMlEzOjVizszN	MoXXV2FPT0WU
ML-2	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfyTWM2OD1yLkGyOFg1KM7:TR?=	MVzTRW5ITVJ?
MC-IXC	M3PJPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vUV2lEPTB;MD6xNlg1OyEQvF2=	NHrFT2lUSU6JRWK=
KYSE-140	M4TaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTuTWM2OD1yLkGzNFQyKM7:TR?=	MXHTRW5ITVJ?
DOHH-2	NHjxSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPQTWM2OD1yLkGzNFY1KM7:TR?=	M1vxNnNCVkeHUh?=
MEL-JUSO	NH;pN3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwMUOxNlgh\|ryP	MkLoV2FPT0WU
P30-OHK	M17TW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTnXlNkUUN3ME2wMlE{OTZizszN	M1rtc3NCVkeHUh?=
CTB-1	M4G0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DLO2lEPTB;MD6xN\|MzPSEQvF2=	MWfTRW5ITVJ?
ACHN	NIPHPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwMUOzOlkh\|ryP	MUXTRW5ITVJ?
ES5	NYXXfJlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;2SoFKSzVyPUCuNVM1PzZizszN	MXTTRW5ITVJ?
SF539	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fQUmlEPTB;MD6xN\|Y5KM7:TR?=	MnLUV2FPT0WU
D-283MED	MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHvcW5IUUN3ME2wMlE{Pjh5IN88US=>	M{PqTHNCVkeHUh?=
OVCAR-5	NVrBT5hFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXU[5oyUUN3ME2wMlE{QDl2IN88US=>	NW\xWW5rW0GQR1XS
RPMI-8866	MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDMfIR1UUN3ME2wMlE{QTJ3IN88US=>	NW\OOJJUW0GQR1XS
PANC-03-27	M{D0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\EbJlKSzVyPUCuNVQzQDhizszN	MV\TRW5ITVJ?
M14	NUL5V3dFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\xeXZVUUN3ME2wMlE1PDZ\|IN88US=>	NGHUUIhUSU6JRWK=
D-566MG	MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLwTWM2OD1yLkG0Olkh\|ryP	Mn35V2FPT0WU
Ramos-2G6-4C10	NETKfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rHbWlEPTB;MD6xOFg1OiEQvF2=	MnnYV2FPT0WU
NOS-1	M3:wTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnSTWM2OD1yLkG0PVY4KM7:TR?=	NGPCe5RUSU6JRWK=
YH-13	NF[ybGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\rTWM2OD1yLkG1Olc1KM7:TR?=	M{[yOHNCVkeHUh?=
NB17	NGLUU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwMUW3PFYh\|ryP	NWfIb2o6W0GQR1XS
U-2-OS	MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwMUW4OFch\|ryP	MoLTV2FPT0WU
ES7	NW\EdZBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLWTWM2OD1yLkG2NFEyKM7:TR?=	NXizWHFVW0GQR1XS
LoVo	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPyTWM2OD1yLkG2NVY3KM7:TR?=	NFHCOXZUSU6JRWK=
QIMR-WIL	M1HnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwMU[zNVEh\|ryP	MWjTRW5ITVJ?
ESS-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjjTXNKSzVyPUCuNVY1OTNizszN	MYXTRW5ITVJ?
LAMA-84	M{HjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnaenBRUUN3ME2wMlE3PTB\|IN88US=>	MV7TRW5ITVJ?
TGBC24TKB	NUPJcItnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjkTWM2OD1yLkG2OVM2KM7:TR?=	NUjRSpBKW0GQR1XS
KU812	NV76UJp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\LSm0{UUN3ME2wMlE3QDNizszN	M3LScnNCVkeHUh?=
KARPAS-45	NUDwTlJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPDTWM2OD1yLkG2PFQ4KM7:TR?=	NGW1ZXBUSU6JRWK=
ACN	MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHKXHFKSzVyPUCuNVcyPzFizszN	M3vTVnNCVkeHUh?=
RPMI-8226	M{nIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwMUe0OlQh\|ryP	Ml;PV2FPT0WU
GR-ST	NHXuR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTBwMUe4Nlch\|ryP	NG[wUpBUSU6JRWK=
SK-UT-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HpWWlEPTB;MD6xPFU6QSEQvF2=	NYjoe2Y3W0GQR1XS
SK-N-AS	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjWfZROUUN3ME2wMlE5QDF3IN88US=>	NHnWfppUSU6JRWK=
EW-1	NVrsWWcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17lZWlEPTB;MD6xPFkxPSEQvF2=	Mmq5V2FPT0WU
5637	NEHiN5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\SOmtKSzVyPUCuNVkzPzhizszN	NF\KR3FUSU6JRWK=
GI-1	NFfUUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\lTWlEPTB;MD6xPVU3OSEQvF2=	Mn7XV2FPT0WU
NCI-H1395	NH;ZO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfYZ2F3UUN3ME2wMlE6PzZzIN88US=>	MWPTRW5ITVJ?
CHP-212	M2jHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\oTWM2OD1yLkG5O\|gzKM7:TR?=	NYHi[\|NmW0GQR1XS
A427	NYDUVWtYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTnXnMzUUN3ME2wMlE6QDN{IN88US=>	NYXTR4V[W0GQR1XS
BE-13	M1Tyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7SO\|BKSzVyPUCuNlAyOTdizszN	M3jkS3NCVkeHUh?=
RS4-11	MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjsT21KSzVyPUCuNlA{OThizszN	M2LiNXNCVkeHUh?=
TI-73	M{PxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jqOWlEPTB;MD6yNFg4OyEQvF2=	NFrpWY5USU6JRWK=
HAL-01	NH;1NVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjrU3dNUUN3ME2wMlIxQTdizszN	MYPTRW5ITVJ?
KY821	MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTlZmVKSzVyPUCuNlE1OjlizszN	NFL2N\|hUSU6JRWK=
H4	NWjZWGM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEezdohKSzVyPUCuNlIxPjJizszN	MoOyV2FPT0WU
EPLC-272H	NG\BZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHhTWM2OD1yLkKyNFY5KM7:TR?=	MnzvV2FPT0WU
COR-L105	M1\XSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXGeJdOUUN3ME2wMlIzOjN3IN88US=>	NV23V2NlW0GQR1XS
769-P	NVy3NpR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHpTWM2OD1yLkKyNlk5KM7:TR?=	NIjPfnhUSU6JRWK=
HEL	MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\CTWM2OD1yLkKyOFU1KM7:TR?=	NYSzWmdVW0GQR1XS
VA-ES-BJ	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInJWZdKSzVyPUCuNlI2PTdizszN	NHjKSVhUSU6JRWK=
IST-MEL1	Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3P5fmlEPTB;MD6yNlU4KM7:TR?=	MXTTRW5ITVJ?
KYSE-270	MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{X6cmlEPTB;MD6yNlY{OyEQvF2=	NGjVT4VUSU6JRWK=
RH-1	NHPCT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonwTWM2OD1yLkKyOlY3KM7:TR?=	MWjTRW5ITVJ?
JVM-3	MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkH2TWM2OD1yLkKzNFM3KM7:TR?=	Mn\PV2FPT0WU
RPMI-7951	NH[3coRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwMkOwOVYh\|ryP	M1vy[nNCVkeHUh?=
JAR	NG\aXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnRUW5yUUN3ME2wMlI{OjN6IN88US=>	M2fyVHNCVkeHUh?=
MOLT-4	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TRXGlEPTB;MD6yN\|g2KM7:TR?=	M3nL[nNCVkeHUh?=
ALL-PO	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkT5TWM2OD1yLkK0NlQ{KM7:TR?=	M32yXnNCVkeHUh?=
SNU-387	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfC[VNFUUN3ME2wMlI1OzN7IN88US=>	MmTBV2FPT0WU
IGROV-1	Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3SSolOUUN3ME2wMlI1PDBzIN88US=>	NW\ZXlJNW0GQR1XS
MPP-89	Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjHZlJrUUN3ME2wMlI1PDVzIN88US=>	MV;TRW5ITVJ?
T98G	M3P5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTBwMkS1Olgh\|ryP	NUTneHcyW0GQR1XS
NCI-H510A	NIXuTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fnUGlEPTB;MD6yOFYzPiEQvF2=	NX3zfG9bW0GQR1XS
KOSC-2	MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrEW3c4UUN3ME2wMlI1PjdzIN88US=>	MmHLV2FPT0WU
NCI-H23	NGG1S2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3XTWM2OD1yLkK0O\|YyKM7:TR?=	MUfTRW5ITVJ?
MC116	MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXJUWd4UUN3ME2wMlI2PjV2IN88US=>	MYLTRW5ITVJ?
8-MG-BA	M1HsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWH1[283UUN3ME2wMlI2PzZ6IN88US=>	NVu0UIpPW0GQR1XS
ABC-1	MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwMk[wOlQh\|ryP	NEKwPW1USU6JRWK=
J-RT3-T3-5	NUnodJRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3WxTmlEPTB;MD6yOlY4QCEQvF2=	MYPTRW5ITVJ?
NCI-SNU-1	MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnNUGpKSzVyPUCuNlcxPTlizszN	MYjTRW5ITVJ?
HCC1395	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwMkewPFkh\|ryP	Ml64V2FPT0WU
BB65-RCC	M{Cx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMkewPVch\|ryP	M4mzPXNCVkeHUh?=
NCI-H1755	NILhXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3neW5VUUN3ME2wMlI4OzB2IN88US=>	NYHG[4VqW0GQR1XS
OVCAR-3	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHYTWM2OD1yLkK3N\|g2KM7:TR?=	NUf6WnRiW0GQR1XS
MKN45	M2\4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTwTWZzUUN3ME2wMlI4QThizszN	MmWwV2FPT0WU
TYK-nu	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXaTWM2OD1yLkK4NFYh\|ryP	Mn3XV2FPT0WU
SNU-C2B	MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2S3RWlEPTB;MD6yPFE{PCEQvF2=	MXPTRW5ITVJ?
H-EMC-SS	NXPHNXF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwMkizOVQh\|ryP	NIfiXm1USU6JRWK=
CAKI-1	NX;pV3FGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwMki2PEDPxE1?	NVj5em51W0GQR1XS
EW-24	NFX2O2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTvTWM2OD1yLkK4PVEh\|ryP	M4jvfXNCVkeHUh?=
RXF393	NEPlXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4T4cmlEPTB;MD6yPVAxQCEQvF2=	NVXQd2x1W0GQR1XS
CCRF-CEM	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnoT3RKSzVyPUCuNlkyPTRizszN	Ml;NV2FPT0WU
HOP-92	Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILzfGlKSzVyPUCuNlkzPzlizszN	Mm\sV2FPT0WU
COLO-684	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfucm1KSzVyPUCuNlk1ODZizszN	NInKNlFUSU6JRWK=
NCI-H28	M3;oSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwMkm3NFQh\|ryP	M1;xe3NCVkeHUh?=
HuO9	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX30dXd4UUN3ME2wMlI6Pzl\|IN88US=>	MYXTRW5ITVJ?
SF295	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfRUIR1UUN3ME2wMlI6QDB{IN88US=>	M4PXSXNCVkeHUh?=
COLO-829	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXr5dGpFUUN3ME2wMlI6QDR3IN88US=>	M1\pU3NCVkeHUh?=
MSTO-211H	NF3iOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;OTWM2OD1yLkK5PFU2KM7:TR?=	MkjDV2FPT0WU
MDA-MB-361	Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXz6RWk6UUN3ME2wMlI6QDl4IN88US=>	NXHCbY04W0GQR1XS
FTC-133	Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTGTWM2OD1yLkOwNlY2KM7:TR?=	Mm\DV2FPT0WU
Mewo	NGe0R5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\QOYxKSzVyPUCuN\|A1OzFizszN	NG\XUXVUSU6JRWK=
HCC70	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPCUlFtUUN3ME2wMlMxPjZ3IN88US=>	M4nwXnNCVkeHUh?=
BB30-HNC	NGTqTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLsbVhKSzVyPUCuN\|E2OjVizszN	MWfTRW5ITVJ?
LCLC-97TM1	NFPYfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwM{G1OlYh\|ryP	MVfTRW5ITVJ?
HCC2998	NYXKRYxyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGWyS4dKSzVyPUCuN\|E3PSEQvF2=	MnjYV2FPT0WU
NBsusSR	NHLi[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\4TWM2OD1yLkOxPFE6KM7:TR?=	MV;TRW5ITVJ?
OVCAR-4	M2nQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTMTWM2OD1yLkOyNFIyKM7:TR?=	M3fXb3NCVkeHUh?=
NCI-H209	NYPxd\|lpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLGNFFKSzVyPUCuN\|I{PTNizszN	Mmn3V2FPT0WU
ChaGo-K-1	NHXVflhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY[zeFNLUUN3ME2wMlMzPDh7IN88US=>	MlzlV2FPT0WU
KALS-1	NHnscJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzZTWM2OD1yLkOyOVk1KM7:TR?=	NY\qVZFpW0GQR1XS
D-423MG	NFjXcJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fzZWlEPTB;MD6zN\|E1OiEQvF2=	NU[3cpRnW0GQR1XS
Detroit562	M1rFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHBWm9KSzVyPUCuN\|M{PDNizszN	MXfTRW5ITVJ?
HT-144	NEfidplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfvbW9GUUN3ME2wMlM{QDFizszN	NFvBW4tUSU6JRWK=
MEG-01	NFfxbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXOTWM2OD1yLkO0OVg1KM7:TR?=	M3XOfHNCVkeHUh?=
BV-173	NXO4dIVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTBwM{S1PVYh\|ryP	NWrYXYRLW0GQR1XS
MZ7-mel	M13xfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInjNnpKSzVyPUCuN\|Q3PzdizszN	NVTjRXVWW0GQR1XS
C32	NFPmb3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwM{S2PFIh\|ryP	M3XQdHNCVkeHUh?=
DU-4475	NX;re29NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwM{S4O\|Uh\|ryP	NX3QfFdFW0GQR1XS
KP-N-YN	M{fz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTBwM{S4PFch\|ryP	MXPTRW5ITVJ?
MKN1	M{nWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn6xTWM2OD1yLkO1NFAzKM7:TR?=	M2DM[3NCVkeHUh?=
8505C	NGDqfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwM{WwNFIh\|ryP	MnHWV2FPT0WU
OVCAR-8	NHrleplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfpT2tKSzVyPUCuN\|U2QDRizszN	Mmn5V2FPT0WU
NH-12	NHzHS\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnhR2FWUUN3ME2wMlM2Pjl4IN88US=>	NF3leGRUSU6JRWK=
COR-L88	NInyUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\KPWlEPTB;MD6zOlQ5OiEQvF2=	MoDCV2FPT0WU
T-24	NIfmelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwM{[5PFUh\|ryP	NYXoR5dkW0GQR1XS
MIA-PaCa-2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFr5WZRKSzVyPUCuN\|c1QTdizszN	MUfTRW5ITVJ?
LS-411N	MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\ybFNKSzVyPUCuN\|c3ODZizszN	M3jTXnNCVkeHUh?=
TK10	NXnBbWpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;NV\|NKSzVyPUCuN\|c6PDhizszN	MXfTRW5ITVJ?
SW1990	Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwM{izOVMh\|ryP	NGq3WGRUSU6JRWK=
GAMG	NX;4b25KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\kcpVDUUN3ME2wMlM5PTZ5IN88US=>	MojyV2FPT0WU
G-361	Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwM{i3NVIh\|ryP	MnXrV2FPT0WU
Ca-Ski	MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwM{i3PVIh\|ryP	NXnDd4djW0GQR1XS
786-0	Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk[3TWM2OD1yLkO4PFI{KM7:TR?=	M2PaRnNCVkeHUh?=
MHH-NB-11	NEm5VWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwM{i5O{DPxE1?	NFXYbohUSU6JRWK=
OE33	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTTVIl[UUN3ME2wMlM6OTF6IN88US=>	NGroVYhUSU6JRWK=
SW954	Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTCVWVKSzVyPUCuOFAyOzFizszN	NWrsOGFZW0GQR1XS
KYSE-180	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml:3TWM2OD1yLkSwNVUyKM7:TR?=	M2j0U3NCVkeHUh?=
NCI-H720	NHnoU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7BXnVKSzVyPUCuOFAyQTFizszN	MXTTRW5ITVJ?
COR-L23	NIflTVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjSNo9KSzVyPUCuOFAzQDZizszN	M2LiW3NCVkeHUh?=
PFSK-1	NY\CVYhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHpdmVmUUN3ME2wMlQyODl{IN88US=>	NUThXmV3W0GQR1XS
FADU	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fzdGlEPTB;MD60NVE4OiEQvF2=	MWXTRW5ITVJ?
GP5d	M3nvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33nOWlEPTB;MD60NVIzPSEQvF2=	M{G0eXNCVkeHUh?=
PC-14	MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzQT5BKSzVyPUCuOFE3PjFizszN	MXLTRW5ITVJ?
SJSA-1	NVmzR3dxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M160NmlEPTB;MD60NVcyPCEQvF2=	MnfNV2FPT0WU
D-336MG	NX;5W3hoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzrS2pKSzVyPUCuOFIyOzhizszN	NXfnVZZtW0GQR1XS
LOXIMVI	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDR[4ZKSzVyPUCuOFI5QDVizszN	M{XteHNCVkeHUh?=
EFO-27	M3rCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTuZWRpUUN3ME2wMlQ{ODR7IN88US=>	NX3meYljW0GQR1XS
A2780	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TCeGlEPTB;MD60N\|E3OiEQvF2=	NHXRToJUSU6JRWK=
CAL-12T	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nGV2lEPTB;MD60N\|I5QCEQvF2=	M1G0dXNCVkeHUh?=
ES6	M3nFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHLfVdEUUN3ME2wMlQ1OTh3IN88US=>	NGS2VFRUSU6JRWK=
HCE-T	NVf1[4Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnm2TWM2OD1yLkS0NVg4KM7:TR?=	NHPWVnVUSU6JRWK=
SK-MES-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmG4TWM2OD1yLkS0Nlk{KM7:TR?=	NYnzeWRVW0GQR1XS
Daoy	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwNEWxNFMh\|ryP	MVzTRW5ITVJ?
A2058	NGD2dHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XVXGlEPTB;MD60OVE{PiEQvF2=	M3vjfHNCVkeHUh?=
Hs-578-T	MojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrMNmI2UUN3ME2wMlQ2Ojd6IN88US=>	M2fNZXNCVkeHUh?=
TE-11	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LnbmlEPTB;MD60OVI6OyEQvF2=	NUj2b\|hjW0GQR1XS
GI-ME-N	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwNEW0OkDPxE1?	MkPwV2FPT0WU
D-392MG	Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwNEW2NVIh\|ryP	MYPTRW5ITVJ?
MOLT-13	NFT3cXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPzO5JKSzVyPUCuOFYzQTRizszN	NXT0Z\|RQW0GQR1XS
SK-NEP-1	NXHON5lGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7jTWM2OD1yLkS2OFE6KM7:TR?=	M3H0fXNCVkeHUh?=
KS-1	NXezR5V[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\OS\|NKSzVyPUCuOFY3ODNizszN	NWPRR\|VPW0GQR1XS
HuP-T4	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPzZ3JKSzVyPUCuOFY5PjhizszN	MUHTRW5ITVJ?
NCI-H1563	M3jJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrBVGhKSzVyPUCuOFcxOzVizszN	MYrTRW5ITVJ?
U031	MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTBwNEiyN\|Qh\|ryP	M4XZOnNCVkeHUh?=
HSC-3	NHK4TZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTBwNEi2NlYh\|ryP	NV3PeFFDW0GQR1XS
HT-3	M33yOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjCO5d1UUN3ME2wMlQ6ODNizszN	MYrTRW5ITVJ?
HGC-27	NV73Z5pRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwNEmxNVUh\|ryP	NVLCVIZzW0GQR1XS
HT-1080	NIHTfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIS2d2lKSzVyPUCuOFkzPyEQvF2=	NEDrSoxUSU6JRWK=
RT-112	NIjOeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwNEm5NlEh\|ryP	M2nlOnNCVkeHUh?=
A375	NWPVb5QzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TmNWlEPTB;MD60PVkzOiEQvF2=	NF\LcGxUSU6JRWK=
SW626	NF\jfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIn6V5pKSzVyPUCuOVA3OzNizszN	NXPiSIZUW0GQR1XS
SBC-5	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHEeWM6UUN3ME2wMlUyOzR2IN88US=>	NXPZTpVPW0GQR1XS
CAL-51	NV\x[2dQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37Kd2lEPTB;MD61NVQ{PyEQvF2=	NGC0W3FUSU6JRWK=
RKO	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwNUKwNVkh\|ryP	Mkn2V2FPT0WU
HC-1	NHKwU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojsTWM2OD1yLkWyNVE1KM7:TR?=	MVfTRW5ITVJ?
CHL-1	NVm1dWRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkmwTWM2OD1yLkWyOVUyKM7:TR?=	M4rKSXNCVkeHUh?=
SK-N-DZ	NVy0XnI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLZTWM2OD1yLkWzNFc5KM7:TR?=	MWPTRW5ITVJ?
SNU-423	Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;6fJBsUUN3ME2wMlU{PDZ4IN88US=>	MWXTRW5ITVJ?
NB13	M1jFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nHdmlEPTB;MD61N\|Y2PyEQvF2=	MmX3V2FPT0WU
EW-16	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfoUmdKSzVyPUCuOVM4PzRizszN	MoeyV2FPT0WU
A704	MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonqTWM2OD1yLkWzPFgyKM7:TR?=	MkPWV2FPT0WU
Ca9-22	M1\rSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwNUSwO\|ch\|ryP	MVzTRW5ITVJ?
NCI-H1299	M2LYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTBwNUW1PEDPxE1?	NFnTbo1USU6JRWK=
LB771-HNC	NUTlTpJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnK0TWM2OD1yLkW1PVM{KM7:TR?=	M{\odnNCVkeHUh?=
EW-11	NXTTeG5VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwNU[zNlYh\|ryP	MkXKV2FPT0WU
LC-2-ad	M4TyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILZdFlKSzVyPUCuOVY2OjJizszN	NFG4W2FUSU6JRWK=
KNS-62	NWDHbJlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjHfWVKSzVyPUCuOVY2PTNizszN	M1PXfHNCVkeHUh?=
CAL-62	NUTSNFJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzSTWM2OD1yLkW3NVIyKM7:TR?=	NGLae49USU6JRWK=
SF126	NUTPdlNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDhPVBxUUN3ME2wMlU4PDJzIN88US=>	Ml[xV2FPT0WU
OMC-1	M2DKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PwTWlEPTB;MD61O\|Q6PyEQvF2=	M4n0OnNCVkeHUh?=
AGS	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\tT2lEPTB;MD61PFE3OiEQvF2=	NE\K[GdUSU6JRWK=
EW-22	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYW5ZXBsUUN3ME2wMlU5Ozd3IN88US=>	M1iyeXNCVkeHUh?=
KP-N-YS	M1q0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLjdmVKUUN3ME2wMlU5Ozh{IN88US=>	MWPTRW5ITVJ?
BFTC-909	MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjLTWM2OD1yLkW4PFM{KM7:TR?=	M1mxZXNCVkeHUh?=
PSN1	NGXQcG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHj2XJBKSzVyPUCuOVkyOThizszN	MnG0V2FPT0WU
NB10	NXzuZ2w3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwNUmxNlkh\|ryP	M{f6U3NCVkeHUh?=
COLO-800	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwNkCzNlgh\|ryP	MmjWV2FPT0WU
647-V	Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jLNGlEPTB;MD62NVc5PyEQvF2=	MV\TRW5ITVJ?
VM-CUB-1	NUjqOI5JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDHSWltUUN3ME2wMlYyQDZzIN88US=>	NVPlcpY4W0GQR1XS
OS-RC-2	NHjQSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwNkKwNUDPxE1?	MY\TRW5ITVJ?
IST-SL1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPxZnByUUN3ME2wMlYzPzh6IN88US=>	MnrEV2FPT0WU
NCI-H661	Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwNkO3NVIh\|ryP	NHP5dFZUSU6JRWK=
ETK-1	NX;2OlJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHrdI9uUUN3ME2wMlY{PzJzIN88US=>	MWrTRW5ITVJ?
SW1710	NGK5VnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TZT2lEPTB;MD62OFAzOyEQvF2=	MkjqV2FPT0WU
GCT	NFXxeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIflZYhKSzVyPUCuOlQ6OzVizszN	NGfDdHlUSU6JRWK=
SKG-IIIa	MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3PemtKSzVyPUCuOlUxOzZizszN	NES5[\|NUSU6JRWK=
LU-134-A	MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHe3fXBKSzVyPUCuOlU3PSEQvF2=	M1zmSXNCVkeHUh?=
Becker	MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LYfGlEPTB;MD62OVgxPSEQvF2=	MkLpV2FPT0WU
PANC-08-13	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwNk[wOlgh\|ryP	M4[4N3NCVkeHUh?=
SW620	M4rBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPxVWxHUUN3ME2wMlY3OjJ\|IN88US=>	MkPIV2FPT0WU
AsPC-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HGPWlEPTB;MD62OlM3OSEQvF2=	MWXTRW5ITVJ?
LXF-289	M1PTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoL4TWM2OD1yLk[3OlI2KM7:TR?=	Mn;hV2FPT0WU
RERF-LC-MS	MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEW0dHZKSzVyPUCuOlc3PzFizszN	NVXOTJZmW0GQR1XS
NCI-H1355	NU\VR4l6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHvOGxKSzVyPUCuOlc5PTJizszN	M1vMTHNCVkeHUh?=
23132-87	NITPPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDzUpVKSzVyPUCuOlg{ODZizszN	NUPSWY9vW0GQR1XS
BHY	NH31bnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\5UWlEPTB;MD62PFgxPCEQvF2=	NV7aN5RQW0GQR1XS
C2BBe1	MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TKU2lEPTB;MD62PFkzQCEQvF2=	MVvTRW5ITVJ?
A172	MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzuTWM2OD1yLk[5NlE4KM7:TR?=	MVLTRW5ITVJ?
NCI-H727	NF\i[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX:1cHIzUUN3ME2wMlY6QDF{IN88US=>	M33JR3NCVkeHUh?=
NB69	NIHNeXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLTelVbUUN3ME2wMlcxPTR7IN88US=>	NHXCVFZUSU6JRWK=
HCC1937	MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwN{C2N\|Eh\|ryP	MlfkV2FPT0WU
HuCCT1	NUjOflg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\ZZmlEPTB;MD63NFc3PSEQvF2=	MmfaV2FPT0WU
HH	MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XmfmlEPTB;MD63NFc5OSEQvF2=	M3jOPHNCVkeHUh?=
MN-60	NWHNVXFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwN{KxNlQh\|ryP	M4faR3NCVkeHUh?=
CFPAC-1	NHvKNndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHGRYVtUUN3ME2wMlczOjV5IN88US=>	NV3XdJQ4W0GQR1XS
HOP-62	NYXHOWY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfGbWlkUUN3ME2wMlczPjJizszN	M{GwXXNCVkeHUh?=
EW-3	NXniXXI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HnemlEPTB;MD63N\|U2OiEQvF2=	M1KxRXNCVkeHUh?=
SW1417	NVu0XG9FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTBwN{O1PVMh\|ryP	MlPtV2FPT0WU
NCI-H1155	MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTtTWM2OD1yLkezPFY1KM7:TR?=	NVewU202W0GQR1XS
CAL-54	NHLsW\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fWfmlEPTB;MD63OFA{KM7:TR?=	Mnn0V2FPT0WU
Saos-2	NVfnO2VyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PsbWlEPTB;MD63OFU5PCEQvF2=	MkS2V2FPT0WU
NCI-H446	M2TtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLhR2hkUUN3ME2wMlc1QDB4IN88US=>	M37uSXNCVkeHUh?=
LS-513	M{X1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXTTWM2OD1yLke0PVA5KM7:TR?=	MYLTRW5ITVJ?
PA-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwN{S5Olgh\|ryP	MlTxV2FPT0WU
HCC38	MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jNN2lEPTB;MD63OFk5PCEQvF2=	M4X6NXNCVkeHUh?=
DMS-273	NF\XclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;tWIVKSzVyPUCuO\|U1PTZizszN	NWK4NHBNW0GQR1XS
U-266	M{HjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\HTWM2OD1yLke2NlYzKM7:TR?=	MYrTRW5ITVJ?
HL-60	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfsUGVKSzVyPUCuO\|c{PTVizszN	NIDsV\|RUSU6JRWK=
UACC-62	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\JR2lEPTB;MD63O\|U2OyEQvF2=	NGe1d4lUSU6JRWK=
DoTc2-4510	M4m2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LC[2lEPTB;MD63PFIyOSEQvF2=	NEixWZdUSU6JRWK=
SW982	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HmNmlEPTB;MD63PFQ{OiEQvF2=	Mk\2V2FPT0WU
8305C	Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXtTWM2OD1yLke4PVM6KM7:TR?=	M{O0NXNCVkeHUh?=
SW48	NHjNUFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfDTWM2OD1yLke5NlQh\|ryP	Mn\HV2FPT0WU
NB5	M{K2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWezOHN4UUN3ME2wMlc6PjVzIN88US=>	MmLqV2FPT0WU
J82	NInvPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwOEC0PFch\|ryP	M2HIdXNCVkeHUh?=
HDLM-2	M2ryRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTlTWM2OD1yLkixN\|Q6KM7:TR?=	M1PQS3NCVkeHUh?=
HEC-1	M1\tTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjMTWM2OD1yLkixN\|cyKM7:TR?=	NWLnU2RlW0GQR1XS
AU565	NUnyfoh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;CPHRKSzVyPUCuPFI1PCEQvF2=	Ml75V2FPT0WU
KYSE-520	NXG2bnBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\PTWM2OD1yLkiyOlM3KM7:TR?=	NW\2PFhZW0GQR1XS
HTC-C3	NFH5ZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LySGlEPTB;MD64N\|Q4PCEQvF2=	NInuOGdUSU6JRWK=
AN3-CA	NIHvXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzpTWM2OD1yLkizO\|EyKM7:TR?=	MX;TRW5ITVJ?
KG-1	M{jyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWSxZlBtUUN3ME2wMlg1PDh2IN88US=>	NWrJ[4dEW0GQR1XS
NCI-N87	MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLyOpBlUUN3ME2wMlg1PTV4IN88US=>	MonsV2FPT0WU
HN	NIn3VlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFWyRVBKSzVyPUCuPFQ2QTFizszN	NHPIVJhUSU6JRWK=
SiHa	M3\4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fFeWlEPTB;MD64OVg5OiEQvF2=	NXG3doVPW0GQR1XS
C-33-A	NGjJR41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPnTWM2OD1yLki2NVg2KM7:TR?=	MWPTRW5ITVJ?
A673	M13hcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwOE[1N\|Yh\|ryP	MYfTRW5ITVJ?
HSC-2	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFT2c29KSzVyPUCuPFc{OzRizszN	M3vmcnNCVkeHUh?=
LN-405	MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwOEe3N\|Eh\|ryP	NG\lcnpUSU6JRWK=
HOS	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\kTWM2OD1yLki3PVk2KM7:TR?=	M4jjUnNCVkeHUh?=
SF268	M2rZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTBwOEiwPVch\|ryP	NWH4XXF{W0GQR1XS
DJM-1	NEL6[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPJTWM2OD1yLki4OlAzKM7:TR?=	NXztVGczW0GQR1XS
HT-29	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwOEm0NVch\|ryP	M2\P[3NCVkeHUh?=
NCI-H292	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfyTWM2OD1yLki5O\|c4KM7:TR?=	MWHTRW5ITVJ?
UM-UC-3	NGS4TVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rZOmlEPTB;MD65NFMyPiEQvF2=	NHSybIVUSU6JRWK=
VMRC-RCZ	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwOUC1O\|gh\|ryP	M1Xac3NCVkeHUh?=
D-263MG	MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TsO2lEPTB;MD65NFk1OyEQvF2=	NFnqd5ZUSU6JRWK=
TE-10	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrVTWM2OD1yLkmwPVg1KM7:TR?=	MWrTRW5ITVJ?
SW1088	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwOUG1OVIh\|ryP	M2HLd3NCVkeHUh?=
NCI-H1048	NGn1cG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPiTGVKSzVyPUCuPVE5PTJizszN	NVTvTGx[W0GQR1XS
A431	NIm0RphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzGTWM2OD1yLkmyOFUzKM7:TR?=	MU\TRW5ITVJ?
SW1783	M1\VPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTBwOUOyOVEh\|ryP	MWfTRW5ITVJ?
NCI-H2452	NXrQOmd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkP3TWM2OD1yLkmzOVU4KM7:TR?=	M4\meXNCVkeHUh?=
OAW-42	MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnaV2dtUUN3ME2wMlk{PjZ3IN88US=>	M3m5T3NCVkeHUh?=
HuO-3N1	NE\YT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnlUVZXUUN3ME2wMlk1ODl{IN88US=>	MkHIV2FPT0WU
K5	M4LG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvDTWM2OD1yLkm0NVI4KM7:TR?=	NYr0S416W0GQR1XS
SW1573	NGPWUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rtN2lEPTB;MD65OFIzPyEQvF2=	M4fQXnNCVkeHUh?=
NCI-H1792	M1PiR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXj4Sm9UUUN3ME2wMlk1OjN5IN88US=>	Mn7XV2FPT0WU
HCC1187	MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDSRo5KSzVyPUCuPVY4PDlizszN	M1\FZnNCVkeHUh?=
HCE-4	Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXLTWM2OD1yLkm2PVYh\|ryP	Mk\vV2FPT0WU
HPAF-II	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPXTWM2OD1yLkm3NFI5KM7:TR?=	M2fnWXNCVkeHUh?=
MEL-HO	M1\aTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nxTGlEPTB;MD65O\|k1PSEQvF2=	NWju[mh4W0GQR1XS
LCLC-103H	M2\i[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LaNGlEPTB;MD65PFAzPyEQvF2=	MkDUV2FPT0WU
CAL-33	NEjWO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvVTWM2OD1yLkm4N\|c5KM7:TR?=	MVHTRW5ITVJ?
NB6	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1[3TmlEPTB;MD65PFQ3OiEQvF2=	MYDTRW5ITVJ?
BFTC-905	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLsTWM2OD1yLkm4OFc{KM7:TR?=	NFnXdXFUSU6JRWK=
NMC-G1	M{TDfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTBwOUi1PVIh\|ryP	M3rJcnNCVkeHUh?=
RCM-1	NX7FNpBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;UeJpKSzVyPUCuPVkzPThizszN	MUHTRW5ITVJ?
COLO-320-HSR	M1nIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFiw[GxKSzVyPUGuNFA1OTJizszN	NETFPZdUSU6JRWK=
NCI-H2030	NIrObo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTFwMEG4NVMh\|ryP	M4Lqb3NCVkeHUh?=
SCC-4	NYDXU3J2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHQTHRKSzVyPUGuNFE5PTlizszN	NITZNlNUSU6JRWK=
KYSE-410	NImwNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXKwZoROUUN3ME2xMlA{PTJizszN	M2fXNXNCVkeHUh?=
NCI-H1650	MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHmToxKSzVyPUGuNFM6PzFizszN	M1u3VXNCVkeHUh?=
S-117	MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTFwMESg{txO	M{TwenNCVkeHUh?=
GAK	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLmR4VRUUN3ME2xMlA2ODd3IN88US=>	M{LKW3NCVkeHUh?=
KYSE-450	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljLTWM2OD1zLkC1N\|M3KM7:TR?=	NIH4cVNUSU6JRWK=
M059J	Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEftZVhKSzVyPUGuNFY5OjhizszN	Ml;KV2FPT0WU
LAN-6	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPHTWM2OD1zLkC3O\|c{KM7:TR?=	NIDUVJdUSU6JRWK=
NCI-H1651	M{jjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jKVWlEPTB;MT6wPVM2OiEQvF2=	M3PrO3NCVkeHUh?=
KMOE-2	NH3ybnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIC5fHdKSzVyPUGuNVA6PzNizszN	Mn3TV2FPT0WU
SN12C	MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlL0TWM2OD1zLkGxO\|g2KM7:TR?=	NFLrRXRUSU6JRWK=
SW900	M3jOOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XPS2lEPTB;MT6xNlI2OSEQvF2=	NVLLRm9xW0GQR1XS
TE-8	NIrDOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTFwMUKyPVEh\|ryP	NEjMelZUSU6JRWK=
HO-1-N-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jXd2lEPTB;MT6xOFM2OyEQvF2=	NUe0cWc4W0GQR1XS
BHT-101	NESyPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljxTWM2OD1zLkG0O\|E1KM7:TR?=	MkfaV2FPT0WU
639-V	M4\aO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPTTWM2OD1zLkG2Olch\|ryP	NEe1TVhUSU6JRWK=
RVH-421	M3viOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33IcmlEPTB;MT6xPVM1PyEQvF2=	NF3udWZUSU6JRWK=
SW780	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\ETWM2OD1zLkG5OVE2KM7:TR?=	MUHTRW5ITVJ?
SNB75	MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{T5TGlEPTB;MT6xPVgyQSEQvF2=	MXjTRW5ITVJ?
U-87-MG	MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjOdGh6UUN3ME2xMlIyOzN2IN88US=>	MlLOV2FPT0WU
TE-1	M4TpSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnPW3BkUUN3ME2xMlIyOzZ5IN88US=>	NUH5[IplW0GQR1XS
CAS-1	MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HTc2lEPTB;MT6yNVQyQCEQvF2=	NYWwZYhGW0GQR1XS
MKN7	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGD1bG1KSzVyPUGuNlE1PzhizszN	NWTpWo5yW0GQR1XS
KM-H2	M2DCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjZR5NNUUN3ME2xMlIyPzd\|IN88US=>	NHH2UVhUSU6JRWK=
NCI-H1693	NEe1d\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jVZWlEPTB;MT6yNlc2QCEQvF2=	NFXTUGRUSU6JRWK=
KGN	M3j2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTFwMkOzOVkh\|ryP	MorrV2FPT0WU
NCI-H2347	NFHxR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVny[4ZTUUN3ME2xMlI{PTJ3IN88US=>	NWfHW5Q4W0GQR1XS
MFM-223	NGDLdG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzKTWM2OD1zLkK0N\|Q{KM7:TR?=	NGrLdoFUSU6JRWK=
OCI-AML2	M{K0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTFwMk[2OlYh\|ryP	NF;oOoJUSU6JRWK=
SAS	NULaV3NTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HrXWlEPTB;MT6yOlY4OiEQvF2=	MXvTRW5ITVJ?
BT-549	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTFwMk[3PFIh\|ryP	MmHSV2FPT0WU
NCI-H2228	MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTFwMki2OEDPxE1?	MWXTRW5ITVJ?
BxPC-3	NVfXV2d{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fkWWlEPTB;MT6zNFY4OiEQvF2=	NWr6OYRKW0GQR1XS
SCH	NEPmRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTFwM{K1NFMh\|ryP	M{e2VHNCVkeHUh?=
GMS-10	MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTFwM{S1OVEh\|ryP	MUXTRW5ITVJ?
GB-1	NV3weVFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTFwM{e1OlQh\|ryP	NXPwcWtkW0GQR1XS
NCI-H520	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\DTWM2OD1zLkO4NVY5KM7:TR?=	M1PZZ3NCVkeHUh?=
GCIY	NHLuZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLtTWM2OD1zLkO5NFUyKM7:TR?=	MUfTRW5ITVJ?
HuH-7	MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1:zVWlEPTB;MT6zPVUxOSEQvF2=	MlvlV2FPT0WU
IA-LM	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTFwM{m5PFYh\|ryP	M364ZXNCVkeHUh?=
BB49-HNC	Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnONWZMUUN3ME2xMlQxOjNzIN88US=>	MWjTRW5ITVJ?
Calu-6	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVr0S2dwUUN3ME2xMlQyOTh5IN88US=>	NWi2RXFFW0GQR1XS
NCI-H650	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnm3TWM2OD1zLkSxO\|k2KM7:TR?=	NGTUUmtUSU6JRWK=
TE-5	NUnnW2JsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLxTWM2OD1zLkSxPVU1KM7:TR?=	NYTaS\|B2W0GQR1XS
KINGS-1	M3W3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;OfJBKSzVyPUGuOFIxOThizszN	M3W4UHNCVkeHUh?=
HCT-116	NIH1eopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTFwNEKxO\|Yh\|ryP	M13J[nNCVkeHUh?=
NCI-H1573	M12xT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TSPWlEPTB;MT60NlI2PyEQvF2=	NVfwW4Z3W0GQR1XS
NCI-H358	NIjBdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTFwNEOxNlgh\|ryP	M{DhWHNCVkeHUh?=
LNCaP-Clone-FGC	Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLxOHl2UUN3ME2xMlQ1OzF7IN88US=>	M{XJPXNCVkeHUh?=
KP-4	M3vK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjyXHhyUUN3ME2xMlQ3OTVzIN88US=>	MWLTRW5ITVJ?
LK-2	NG\ab\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfqTWM2OD1zLkS2N\|gzKM7:TR?=	M1ztPHNCVkeHUh?=
EFM-19	Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljLTWM2OD1zLkS4NVA1KM7:TR?=	NGfRSZZUSU6JRWK=
GT3TKB	M4\NcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rUe2lEPTB;MT60PFYyOyEQvF2=	M2KzRnNCVkeHUh?=
A549	NWPnfnluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTFwNEi4N\|Mh\|ryP	M2OzcXNCVkeHUh?=
no-11	M1f1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTFwNEmwNlYh\|ryP	NF;ZTYJUSU6JRWK=
SK-N-FI	M{\3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LYSmlEPTB;MT60PVM5KM7:TR?=	NYX5OJR5W0GQR1XS
NCI-H2170	NHn4Z41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHUS4VKSzVyPUGuOVI{OTNizszN	MVLTRW5ITVJ?
NCI-H460	M1H0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\o[WpKSzVyPUGuOVI6PjFizszN	Mm\tV2FPT0WU
NCI-H526	NFPxXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTwTWM2OD1zLkWzO\|A3KM7:TR?=	MXfTRW5ITVJ?
KYSE-510	NWTUV\|VLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjVVXdoUUN3ME2xMlU5OjVizszN	MmjhV2FPT0WU
YKG-1	NGXQfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkntTWM2OD1zLkW4N\|I5KM7:TR?=	NYTmXnR5W0GQR1XS
EW-18	NVPNeGptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWi3[Il5UUN3ME2xMlYxOjJ5IN88US=>	MX7TRW5ITVJ?
MDA-MB-231	MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vJUmlEPTB;MT62NFM5KM7:TR?=	NF\Qd5BUSU6JRWK=
HT55	M2fi[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTFwNkC1PVEh\|ryP	M2exSnNCVkeHUh?=
NCI-H1793	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zkTWlEPTB;MT62NVM1PSEQvF2=	MWrTRW5ITVJ?
TE-9	NX3sXIM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPC[ZFKSzVyPUGuOlM1PTZizszN	NEnJVW1USU6JRWK=
DSH1	NFK5TIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3y3O2lEPTB;MT62PVI2PiEQvF2=	M4nVcHNCVkeHUh?=
A101D	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTFwNkm5PFMh\|ryP	M{DmPXNCVkeHUh?=
DB	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\0TWM2OD1zLkewNFY4KM7:TR?=	M2X5Z3NCVkeHUh?=
ME-180	NXLoc2lLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\JUYZKSzVyPUGuO\|E4QDVizszN	M13YOHNCVkeHUh?=
BT-20	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzQNXZiUUN3ME2xMlczPDB5IN88US=>	Ml3KV2FPT0WU
A498	NETyV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXWNFRKSzVyPUGuO\|I6PjNizszN	MmHlV2FPT0WU
UMC-11	NHrrUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHXTWM2OD1zLke2O\|Q6KM7:TR?=	NWfmbZNwW0GQR1XS
EC-GI-10	M4P0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTFwN{e1OVYh\|ryP	NF3zSFVUSU6JRWK=
NCI-H630	NVj2eJJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHjTWM2OD1zLke4OlQzKM7:TR?=	M2XhUnNCVkeHUh?=
EGI-1	NFnR[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXqPHZKSzVyPUGuPFAzPjdizszN	MWjTRW5ITVJ?
22RV1	NYXkS2R{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTFwOEC4OVMh\|ryP	NX7POYE{W0GQR1XS
LS-123	NFrTfFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfKTWM2OD1zLkixNlE1KM7:TR?=	M1Lt[XNCVkeHUh?=
OAW-28	MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFq3OZVKSzVyPUGuPFQ4PDZizszN	MWXTRW5ITVJ?
CaR-1	Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DXe2lEPTB;MT64O\|A4KM7:TR?=	MXTTRW5ITVJ?
HT	NWPwcWNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTFwOEezOFIh\|ryP	Mk\UV2FPT0WU
BCPAP	NVmxRYh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXNcIlMUUN3ME2xMlg5Pjd4IN88US=>	MV;TRW5ITVJ?
RMG-I	NHHGVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTFwOUC3PFch\|ryP	NW[5c2liW0GQR1XS
C8166	NF3LNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7qUG5KSzVyPUGuPVA6OzJizszN	MnPjV2FPT0WU
TGBC1TKB	NU[5eVNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTFwOUKwN\|Uh\|ryP	MYrTRW5ITVJ?
SCC-9	NYqzOmR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\4UI9KSzVyPUGuPVkyODVizszN	NWeyco52W0GQR1XS
EKVX	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTCTWM2OD1{LkCwNVU1KM7:TR?=	NUXodJpOW0GQR1XS
KU-19-19	NXfPUJR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rHWWlEPTB;Mj6wNFM4OiEQvF2=	NV3Jfm55W0GQR1XS
K-562	Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvBcoJUUUN3ME2yMlAxQDl6IN88US=>	M1W1ZXNCVkeHUh?=
SW962	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HPTmlEPTB;Mj6wOFA2QSEQvF2=	MlniV2FPT0WU
MDA-MB-453	NV[0WXhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTJwMEW0OFIh\|ryP	MoPOV2FPT0WU
BPH-1	NYC3N3FLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1n1NGlEPTB;Mj6wO\|A6QCEQvF2=	M1jPd3NCVkeHUh?=
DK-MG	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTJwMEi2NFMh\|ryP	NWjmO\|d{W0GQR1XS
Capan-2	NFnK[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorXTWM2OD1{LkGwNFQyKM7:TR?=	M1jEeHNCVkeHUh?=
SCC-15	NVPyeGViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTJwMUK1OFEh\|ryP	MWXTRW5ITVJ?
DOK	NX\UblRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPKTWM2OD1{LkGzNVQ4KM7:TR?=	NIPCbFJUSU6JRWK=
YAPC	MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFv2N5lKSzVyPUKuNVU{ODdizszN	NWHYe4dwW0GQR1XS
AM-38	MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkCzTWM2OD1{LkG3NFE2KM7:TR?=	NWP1XWdMW0GQR1XS
EFO-21	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTJwMUe3PFgh\|ryP	M3:5Z3NCVkeHUh?=
A388	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17SPGlEPTB;Mj6xPVI4OSEQvF2=	NFHNbHRUSU6JRWK=
RH-18	NYmwNZd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTJwMUmzOlkh\|ryP	NFvnUVZUSU6JRWK=
NCI-H1581	M2DqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7JTWM2OD1{LkG5OVk3KM7:TR?=	MVLTRW5ITVJ?
COLO-668	M{\LdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjheVZKSzVyPUKuNlk6PzNizszN	MYLTRW5ITVJ?
RPMI-2650	NELkfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jBPGlEPTB;Mj6zNlY2QSEQvF2=	NYXpcIpQW0GQR1XS
HMV-II	M1vobWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfqd25NUUN3ME2yMlM{QDZ6IN88US=>	MWrTRW5ITVJ?
NCI-H2342	M1PXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHUSIhKSzVyPUKuN\|Q3ODNizszN	NHriV3lUSU6JRWK=
SH-4	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTJwM{iyNFQh\|ryP	M1zJRnNCVkeHUh?=
L-428	MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TRRmlEPTB;Mj6zPFc6PCEQvF2=	NUDrNGJ[W0GQR1XS
U-118-MG	MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTJwM{m4NFUh\|ryP	MojuV2FPT0WU
RO82-W-1	NIWzfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTpTWM2OD1{LkSzO\|I4KM7:TR?=	MnrTV2FPT0WU
NCI-H2291	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGny[4RKSzVyPUKuOFY6QTRizszN	NHnQb5ZUSU6JRWK=
SK-OV-3	M3Xufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nXN2lEPTB;Mj61NFI1QSEQvF2=	MYfTRW5ITVJ?
NCI-H441	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PCPGlEPTB;Mj61NFMxPSEQvF2=	M1nDeXNCVkeHUh?=
NCI-H2009	MmXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTJwNUK5N\|Qh\|ryP	NFTSXIpUSU6JRWK=
LB2518-MEL	NUjS[FIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTJwNUO3OFch\|ryP	NFSzOIZUSU6JRWK=
PANC-10-05	MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTJwNkGxNVYh\|ryP	NIT4cHVUSU6JRWK=
CAL-85-1	NGXFVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PrU2lEPTB;Mj62OlE3OSEQvF2=	Mn3mV2FPT0WU
PC-3	NVnnfJJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVv4UZh2UUN3ME2yMlY3PjFzIN88US=>	MV7TRW5ITVJ?
COLO-824	MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7TTWM2OD1{Lk[3N\|c1KM7:TR?=	NYLVV3dJW0GQR1XS
D-502MG	MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk[1TWM2OD1{LkewOFA3KM7:TR?=	MkjCV2FPT0WU
SBC-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUH4VpMzUUN3ME2yMlcyPjJ5IN88US=>	NUSxT3ZzW0GQR1XS
CAPAN-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzxTWM2OD1{LkexPVQ6KM7:TR?=	MoDVV2FPT0WU
D-247MG	M3;EWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULvbY93UUN3ME2yMlc{PzV4IN88US=>	M{TEVXNCVkeHUh?=
CAL-39	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPZTWtKSzVyPUKuPFY{QDlizszN	NFXTN2dUSU6JRWK=
NCI-H2087	NEO1[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHqzVFBKSzVyPUKuPFg1OzFizszN	MnrXV2FPT0WU
NB7	M1HmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTJwOUKxN\|kh\|ryP	MUHTRW5ITVJ?
NCI-H1437	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13mSGlEPTB;Mj65NlI2PyEQvF2=	NGrNcGJUSU6JRWK=
RD	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDJTWM2OD1{Lkm5PVM6KM7:TR?=	MXPTRW5ITVJ?
TCCSUP	MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHn0[HFKSzVyPUOuNFI3OzZizszN	M4GxbHNCVkeHUh?=
MKN28	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7oTWM2OD1\|LkCzOFY{KM7:TR?=	NYTocYM5W0GQR1XS
NCI-H596	NIHL[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPqTWM2OD1\|LkC2O\|Eh\|ryP	NH;DdnpUSU6JRWK=
SW948	MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{[3N2lEPTB;Mz6wPVY6OyEQvF2=	MYHTRW5ITVJ?
WM-115	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmW2TWM2OD1\|LkGxPFI4KM7:TR?=	MonZV2FPT0WU
HCC1954	NEnRcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTNwMUKxOFEh\|ryP	M{nLWXNCVkeHUh?=
MS-1	NEDRdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33vcGlEPTB;Mz6xPFQ4PCEQvF2=	Mof6V2FPT0WU
SW13	M4DJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfOXGQzUUN3ME2zMlI{OjZizszN	M2LnNHNCVkeHUh?=
OE19	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnQWppKSzVyPUOuNlg1QDlizszN	M4rtbnNCVkeHUh?=
HT-1197	NUHvdWVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUn4VIhYUUN3ME2zMlI6OTd7IN88US=>	M2LS[XNCVkeHUh?=
HLE	NH30bo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjKdVNQUUN3ME2zMlMzQDFizszN	NFS1UGJUSU6JRWK=
NUGC-3	MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTNwNES3OlEh\|ryP	M{S3OXNCVkeHUh?=
UACC-257	NUP6bGNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTNwNUK0NVch\|ryP	MV\TRW5ITVJ?
SK-MEL-3	M2nuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTNwNUOyNVQh\|ryP	Mn3qV2FPT0WU
KNS-81-FD	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV33VVlVUUN3ME2zMlU3OiEQvF2=	NWLCNZlIW0GQR1XS
MZ1-PC	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvR[lJKSzVyPUOuOVc6QDZizszN	MYTTRW5ITVJ?
KLE	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF[5WIFKSzVyPUOuOVk5PjdizszN	M1G3b3NCVkeHUh?=
NCI-H2052	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3njWWlEPTB;Mz62NFAxQSEQvF2=	MnLUV2FPT0WU
NCI-H1838	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrRUWJyUUN3ME2zMlgyOTF7IN88US=>	NHvWRY5USU6JRWK=
NCI-H1623	NIrid2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTRwMEGzPVYh\|ryP	NFHiRVVUSU6JRWK=
SCC-25	NFm1TVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHCTWM2OD12LkKzOVk4KM7:TR?=	NYPKTJVFW0GQR1XS
CP66-MEL	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPkTWM2OD12LkK1NVkyKM7:TR?=	M2iwXHNCVkeHUh?=
TE-12	NHe1elVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTRwMkmyO\|Eh\|ryP	M{PjTXNCVkeHUh?=
LU-99A	M1\3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLSTWM2OD12LkOxN\|Q2KM7:TR?=	NIHFS2NUSU6JRWK=
CAMA-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnPTWM2OD12LkO1NkDPxE1?	M2jvdHNCVkeHUh?=
SK-MEL-30	NX3nbJp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknxTWM2OD12LkSxPVE{KM7:TR?=	Mlj5V2FPT0WU
KURAMOCHI	NG\MOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrpS2lKSzVyPUSuOFU2OjhizszN	NXzlWXRkW0GQR1XS
BEN	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLqW2VKSzVyPUSuOVI{PjJizszN	NXz0S4JWW0GQR1XS
NCI-H226	MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorMTWM2OD12LkW0PFcyKM7:TR?=	NELOUGpUSU6JRWK=
CAL-27	MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHriZplKSzVyPUSuO\|E3QTRizszN	M2mzeHNCVkeHUh?=
G-401	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfpTWM2OD12LkizPFQyKM7:TR?=	NXLvTZFEW0GQR1XS
CAL-120	Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHqS41KSzVyPUSuPFQ6QTFizszN	NWr3Oo1yW0GQR1XS
DMS-114	NUjHfINCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{X3[2lEPTB;NT6xOFUxPiEQvF2=	NW\J[\|IyW0GQR1XS
KYSE-70	NYnmSHIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1[0TWlEPTB;NT6xOFg2QSEQvF2=	M4fHRnNCVkeHUh?=
NCI-H1648	NYXic3R[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPlS\|d5UUN3ME21MlI6Pzh{IN88US=>	M2\yN3NCVkeHUh?=
MDA-MB-175-VII	NV\6flE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTVwNESwNVQh\|ryP	NVrpZpBkW0GQR1XS
NCI-H2029	NX;1T5lHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\KTWM2OD13LkS4NFIzKM7:TR?=	NH7hfFRUSU6JRWK=
LS-1034	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnPUI1KSzVyPUWuOlY5QDlizszN	NUnBfXp1W0GQR1XS
LB831-BLC	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3SyfWlEPTB;NT63NFM1PSEQvF2=	NXzFW4xoW0GQR1XS
MDA-MB-415	Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XqW2lEPTB;NT63NFgyKM7:TR?=	M33RSnNCVkeHUh?=
TE-6	NW[3W4lnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTVwN{SxPFIh\|ryP	NWTwcms2W0GQR1XS
SK-MEL-24	NFXiU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTVwN{S1OlQh\|ryP	NILvUHJUSU6JRWK=
HUTU-80	M1rUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFmxWWtKSzVyPUWuO\|U{OzNizszN	Mo\iV2FPT0WU
OCUB-M	NIH4PY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nZU2lEPTB;NT63O\|U3OyEQvF2=	NGPNSYhUSU6JRWK=
IGR-1	NED2PXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTMTWM2OD13Lki2PFk1KM7:TR?=	MXfTRW5ITVJ?
NCI-H747	MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTZwMkS1PFUh\|ryP	MVfTRW5ITVJ?
COLO-680N	MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2SzcWlEPTB;Nj6zPVQxOyEQvF2=	MV3TRW5ITVJ?
NB12	MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\QfJM1UUN3ME22Mlc6PzJ{IN88US=>	MlvwV2FPT0WU
SNU-449	NITyR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTZwOUm1PVEh\|ryP	Ml3BV2FPT0WU
D-542MG	MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmn2TWM2OD15LkGyNlk6KM7:TR?=	M1PWPHNCVkeHUh?=
COLO-792	NHLxTZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGO3N\|RKSzVyPUeuPFcyOjdizszN	MYfTRW5ITVJ?
NCI-H810	M4fyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;xTWM2OD16LkCyPVg1KM7:TR?=	M{f4TXNCVkeHUh?=
T47D	M4DyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLFTWM2OD16LkG2NFI1KM7:TR?=	NInNUIFUSU6JRWK=
Calu-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRThwMki4PFYh\|ryP	M1Ha[XNCVkeHUh?=
COLO-741	NF7USmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;FV2lEPTB;OD65N\|A6OyEQvF2=	MWXTRW5ITVJ?
LU-135	Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUiwcZJnUUN3ME25MlA{PDV{IN88US=>	NVHxV5d2W0GQR1XS
COLO-678	NFPpNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTlwMki4OFQh\|ryP	NHLKelRUSU6JRWK=
NCI-H2126	MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfxV5NKSzVyPUmuN\|M6OTlizszN	M3fodnNCVkeHUh?=
SK-MEL-28	NYr3SYZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1m2[WlEPTB;OT61N\|U6PiEQvF2=	NEG1[JVUSU6JRWK=
MFE-280	M3Pkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LzemlEPTB;MUCuNFIzQSEQvF2=	NHfPR4ZUSU6JRWK=
DBTRG-05MG	M4i3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfNTWM2OD1zMD60N\|Y6KM7:TR?=	NXS5PIxjW0GQR1XS
RCC10RGB	MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nnc2lEPTB;MUCuOVI2PSEQvF2=	NFvpcHRUSU6JRWK=
NTERA-S-cl-D1	M3jheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrqTWM2OD1zMD62PFUzKM7:TR?=	MkXPV2FPT0WU
C3A	NGTVbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlf5TWM2OD1zMj6zNVczKM7:TR?=	MlK1V2FPT0WU
MHH-ES-1	MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTldWhKSzVyPUGyMlUzQDRizszN	NG\kSWlUSU6JRWK=
LU-139	MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUm2dVFIUUN3ME2xNk43OzN\|IN88US=>	NInvc5BUSU6JRWK=
KNS-42	NYT1NWdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGO0UZpKSzVyPUGyMlg4PzFizszN	NYLBXmJUW0GQR1XS
MCF7	NHrJOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rnOGlEPTB;MUOuNlM3PSEQvF2=	NYfaWZlOW0GQR1XS
SW872	M{[0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vlWmlEPTB;MUSuOVQ3OSEQvF2=	MYnTRW5ITVJ?
HT-1376	MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37lcWlEPTB;MUSuPFU5OiEQvF2=	NVuxU3k{W0GQR1XS
NCI-SNU-5	M{DBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnP6TWM2OD1zNT6xO\|QyKM7:TR?=	MX3TRW5ITVJ?
NCI-H2405	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTF3LkS0O\|Qh\|ryP	NGLpV\|JUSU6JRWK=
KYSE-150	NETpcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDKUllnUUN3ME2xOU44PjFzIN88US=>	NXT0fHJVW0GQR1XS
SW837	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUm4SFZsUUN3ME2xOk4xOTJ2IN88US=>	MWjTRW5ITVJ?
LU-65	MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\nPItKSzVyPUG5MlczPiEQvF2=	MnXaV2FPT0WU
JEG-3	M1m4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTJyLkO1O\|ch\|ryP	MnXXV2FPT0WU
SK-MEL-1	NWTZRYF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPEeJRKSzVyPUKwMlc5OzZizszN	MoXqV2FPT0WU
SK-HEP-1	NEHjWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPV[4ZIUUN3ME2yNU42PTRzIN88US=>	MUfTRW5ITVJ?
NCI-H1770	M3S5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{G3bWlEPTB;MkOuOFA5PiEQvF2=	Mm\OV2FPT0WU
MG-63	M3q2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTJ\|Lke2O\|Mh\|ryP	NGj0UYJUSU6JRWK=
ECC10	M2DjZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTJ3LkW3NUDPxE1?	NVT1U4t6W0GQR1XS
SW1463	NULXNZRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjGXWdwUUN3ME2yO{45OzF4IN88US=>	MXPTRW5ITVJ?
JVM-2	NFrCdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkj1TWM2OD1{OD6zNlQ5KM7:TR?=	MXTTRW5ITVJ?
HCT-15	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3xNmRKSzVyPUK4MlQyQTJizszN	NVexb4RDW0GQR1XS
CAL-72	NVH1U4txT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTNzLkS5NVIh\|ryP	M{L6fXNCVkeHUh?=
HCC2218	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHqbFVrUUN3ME2zNk45QDV6IN88US=>	M3LVU3NCVkeHUh?=
BT-474	NVnTeZB4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvRTWM2OD1\|Mz6wPFQ{KM7:TR?=	NX7uVnVqW0GQR1XS
NCI-H1092	NITFRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LmWmlEPTB;M{OuOVE1PSEQvF2=	NF\rOoJUSU6JRWK=
Mo-T	M2rjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPyTWM2OD1\|Nz6zOVg2KM7:TR?=	MXHTRW5ITVJ?
DU-145	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLidlZqUUN3ME20NE43Ojl3IN88US=>	MVLTRW5ITVJ?
NCI-H1666	MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTR{LkS0PFgh\|ryP	NGPJVHpUSU6JRWK=
IST-MES1	NU\s[Hd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTR4LkSxPVYh\|ryP	Mnv3V2FPT0WU
SW1116	Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTR6LkG3OVYh\|ryP	NUW2WnNnW0GQR1XS
MZ2-MEL	MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPvTWM2OD12OD61NFI3KM7:TR?=	Mn;XV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pChk1 / Chk1 / Wee1 / p21 / p53 ; PubMed: 29963769 Cancer Med Immunoblotting analysis of CAL39 and SW954 cells showing increase in CHK1 phosphorylation after exposure to AZD7762 for 24 hours. β‐actin is used as loading control. Representative data from n = 3 experiments.	29963769
Growth inhibition assay	Cell viability; PubMed: 23715154 Cancer Discov Lkb1-wt (634, 855, and 857) and Lkb1-null (t2, t4, and t5) cell lines were plated into 96-well plates at 2000 cells/well in 150 ml medium containing the indicated concentrations of AZD7762 or CHIR124 for 3 days. Viable cells were then counted with Dojindo’s Cell Counting Kit-8 assay. The data represent mean ± SD for 3 repeats. GI50 was calculated with GraphPad.	23715154

In vivo

AZD7762 alone at 25 mg/kg shows little antitumor activity in the H460-DNp53 xenograft mice and SW620 xenograft mice, but when administrated in combination with gemcitabine (60 mg/kg), AZD7762 shows significant antitumor efficacy in the two xenografts mice with a log cell kill of 0.9 or percent treated/control (%T/C) of 26 even at low dose of 12.5 mg. Dosing of AZD7762 in combination with gemcitabine (10 mg/kg) in the H460-DNp53 xenograft rat inhibits the tumor volume in a dose-dependent manner with the %T/C values of 48 and 32 for 10 and 20 mg/kg AZD7762, respectively. AZD7762 (25 mg/kg) in combination with irinotecan (25 or 50 mg/kg) causes complete tumor regression in the SW620 xenograft mice with the %T/C increasing significantly to -66% and -67%, respectively. ^[1]

Protocol

Kinase Assay:^[1]	+ Expand Chk1 Kinase Assay: Recombinant human Chk1 is expressed as a glutathione S-transferase fusion in insect cells using a baculovirus vector and purified by glutathione affinity chromatography. A synthetic peptide substrate (N-biotinylaminohexanoyl-KKVSRSGLYRSPMPENLNRPR) for Chk1 is synthesized. Final assay concentrations of peptide and ATP (cold + 40 nCi [³³P]ATP) are 0.8 and 1 μM, respectively. Different concentrations of AZD7762, buffer containing peptide and chk1 kinase and ATP, are added sequentially to a 384-well assay plate. The plate is incubated for 2 hours, reaction is stopped by the addition of buffer containing EDTA and scintillation proximity assay beads, and plates are read using a TopCount reader. Data analysis is carried out to determinate a dose response (IC50).
Cell Research:^[1]	+ Expand Cell lines: HT29, SW620 and MDA-MB-231 cells Concentrations: Dissolved in DMSO, final concentration ~12.5 μM Incubation Time: 20 or 48 hours Method: For the checkpoint abrogation assay, HT29 cells are treated for 2 hours with camptothecin (topoisomerase I inhibitor; 0.07 μg/mL) to induce the G2 checkpoint. Cells are then treated for 20 hours with a 12-point titration of AZD7762 (12.5 μM to 6 nM) plus nocodazole. Cells are fixed with 3.7% formaldehyde for 1 hour, permeabilized with PBS containing 0.05% Triton X, and incubated with anti-phH3 antibody for 1 hour followed by Alexa Fluor 488 anti-rabbit and Hoechst stain for 1 hour. Mitotic index is determined on the ArrayScan and expressed as the percentage of cells undergoing mitosis. For the potentiation assays, SW620 or MDA-MB-231 cells are dosed for 24 hours with a 9-point titration of gemcitabine ranging from 0.01 to 100 nM with a constant dose of AZD7762 (300 nM). After 24 hours, medium is removed and AZD7762 alone is added back to the wells for an additional 24 hours. Cells are then incubated in AZD7762-free medium for an additional 72 hours. The effect on cell proliferation is determined by MTT. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: Male NCr mice implanted s.c. with H460-DNp53 cells or SW620, and male rnu rats implanted s.c. with H460-DNp53 cells Formulation: Formulated in 11.3% hydroxyproplyl-β-cyclodextrin Dosages: ~25 mg/kg Administration: Injection i.v. (Only for Reference)

References

[1] Zabludoff SD, et al. Mol Cancer Ther, 2008, 7(9), 2955-2966.

Solubility (25°C)

In vitro	DMSO	50 mg/mL (137.96 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AZD7762 SDF

Molecular Weight	362.42
Formula	C₁₇H₁₉FN₄O₂S
CAS No.	860352-01-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
If I want to use the inhibitor for i.p. injection, can I use DMSO to dissolve it?
Answer:
Since DMSO has low toxicity with i.p. injection, hydroxyproplyl-β-cyclodextrin is consider a safer co-solvent in compound formulation. In a previous literature report, 11.3% hydroxyproplyl-β-cyclodextrin was used to formulate this compound for i.v. injection.

Chk Signaling Pathway Map

Chk Inhibitors with Unique Features

Selective CHK Inhibitor

MK-8776 (SCH 900776) : Chk1-selective, IC50=3 nM.
Most Potent CHK Inhibitor

CHIR-124 : Chk1, IC50=0.3 nM.
CHK Inhibitor in Clinical Trial

MK-8776 (SCH 900776) : Phase II for Relapsed Acute Myeloid Leukemia.
Classic CHK Inhibitor

PF-477736 : Selective, potent and ATP-competitive Chk1 inhibitor with K_i of 0.49 nM and also inhibits VEGFR2, Aurora-A, FGFR3, Flt3, Fms (CSF1R), Ret and Yes.

Related Chk Products

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
ML141 ^New

ML141 (CID-2950007), is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7).
Rabusertib (LY2603618)

Rabusertib (LY2603618) is a highly selective Chk1 inhibitor with potential anti-tumor activity in a cell-free assay. IC50=7 nM, showing approximately 100-fold more potent against Chk1 than against any of the other protein kinases evaluated.
CHIR-124

CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM in a cell-free assay. It shows 2,000-fold selectivity against Chk2, 500- to 5,000-fold less activity against CDK2/4 and Cdc2.
MK-8776 (SCH 900776)

MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. Phase 2.
PF-477736

PF-477736 is a selective, potent and ATP-competitive Chk1 inhibitor with K_i of 0.49 nM in a cell-free assay and also inhibits VEGFR2, Aurora-A, FGFR3, Flt3, Fms (CSF1R), Ret and Yes. It shows ~100-fold selectivity for Chk1 than Chk2. Phase 1.
Y-27632 2HCl

Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with K_i of 140 nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.
Palbociclib (PD-0332991) HCl

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Alisertib (MLN8237)

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Features:First orally available inhibitor of Aurora A.

Choose Your Country or Region

By Signaling Pathways

By product type

AZD7762

Cited by 35 Publications

Purity & Quality Control

Choose Selective Chk Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download AZD7762 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Chk Signaling Pathway Map

Chk Inhibitors with Unique Features

Related Chk Products

Choose Your Country or Region

By Signaling Pathways

By product type

AZD7762

Cited by 35 Publications

Purity & Quality Control

Choose Selective Chk Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download AZD7762 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Chk Signaling Pathway Map

Chk Inhibitors with Unique Features

Related Chk Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)